Chemotherapy with MOPP versus hybrid MOPP/EVAP in advanced Hodgkin's disease

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Primary study design	Interventional
Study design	Randomised controlled trial
Secondary study design	Randomised controlled trial
Study type	Participant information sheet
Scientific title	Chemotherapy with MOPP versus hybrid MOPP/EVAP in advanced Hodgkin's disease
Study objectives	Not provided at time of registration
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Lymphoma (Hodgkin's)
Intervention	Patients are randomised to one of two chemotherapy regimens: 1. MOPP Regimen: Multi-drug chemotherapy with mustine, vincristine (Oncovin), procarbazine and prednisolone (MOPP) repeated every 4 weeks for a minimum of four courses. 2. MOPP/EVAP Regimen: Multi-drug chemotherapy with MOPP alternating every 2 weeks with etoposide, vinblastine, adriamycin and prednisolone (EVAP) for a minimum of eight courses of chemotherapy (ie four courses each of MOPP and EVAP).
Intervention type	Drug
Phase	Not Applicable
Drug / device / biological / vaccine name(s)
Primary outcome measure(s)	Not provided at time of registration
Key secondary outcome measure(s)	Not provided at time of registration
Completion date	01/10/1993

Participant type(s)	Patient
Age group	Not Specified
Sex
Key inclusion criteria	1. Hodgkin's lymphoma stage IIB, III or IV 2. Staging to include adequate documentation of systemic symptoms, and Computed Tomography (CT) scan (except stage IV) 3. Local hisopathological review of diagnosis 4. No medical contraindications to treatment protocols
Key exclusion criteria	Not provided at time of registration
Date of first enrolment	01/01/1989
Date of final enrolment	01/10/1993

MRC Clinical Trials Unit

London
NW1 2DA
United Kingdom

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary
IPD sharing plan

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes

21/01/2019: No publications found. All search options exhausted.